PHVS · Pharvaris N.V.
$31.41
+2.38% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-11.5
Dividend yield
0.0%
Beta
-2.46
Avg volume
1M
Employees
0K
Daily Change %
2.38%
5 Days Change
10.60%
10 Days Change
2.20%
30 Days Change
-7.23%
60 Days Change
-17.77%
Month to Day Change
-1.06%
Year to Day Change
10.56%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PHVS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-23
Latest call per bank · past 12 months
Bank of America
Buy$44.00
+40.1% vs priceMorgan Stanley
Overweight$62.00
+97.4% vs priceWells Fargo
Overweight$65.00
+106.9% vs priceRBC Capital
Outperform$62.00
+97.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-23 | Bank of America | Upgrade | Neutral → Buy | $44.00 |
| 2026-09-10 | Guggenheim | Maintains | Buy | $40.00 → $44.00 |
| 2026-09-09 | Morgan Stanley | Maintains | Overweight | $46.00 → $62.00 |
| 2026-09-09 | Leerink Partners | Maintains | Outperform | $50.00 → $65.00 |
| 2026-09-09 | Wells Fargo | Maintains | Overweight | $55.00 → $65.00 |
| 2026-09-09 | RBC Capital | Maintains | Outperform | $52.00 → $62.00 |
| 2026-09-09 | Citizens | Maintains | Market Outperform | $75.00 → $79.00 |
| 2026-09-09 | Wedbush | Maintains | Outperform | $42.00 → $50.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 7.6% below the 50-day MA ($33.98).
- bullish: Price vs 200-day MA: Trading 1.9% above the 200-day MA ($30.82).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.25) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($21.59) and high ($38.86).
PHVS Price Chart
Loading chart for PHVS…
Fundamentals
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.